Mid Pharma Company Outlook to 2016

NEW YORK, Jan. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0760621/Mid-Pharma-Company-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Introduction

This analysis examines the outlook for companies in Datamonitor's Mid Pharma peer set. The report encompasses insight into key strategic themes across the group of companies and identifies sales trends using 6-year prescription pharmaceutical sales forecasts for all the companies covered.

Features and benefits

* Gain insight into Mid Pharma companies strategic outlook across the next 6 years* Analyze sales forecasts by company, therapy area, lifecycle stage, and molecule type.

Highlights

Strategic insight into the prospects for Mid Pharma companies over the next six years. Picking out key trends across the companies and comparing performance using a variety of cuts of forecast sales.

Your key questions answered

* Benchmark companies outlook against key rivals across Datamonitor's Mid Pharma peer set* Assess how two companies in particular - Celegene and Gilead - will provide the majority of sales growth momentum within Mid Pharma through to 2016Executive SummaryKey findingsOverview of the Mid Pharma peer setMid Pharma prescription pharma sales performance, 2004–16The Mid Pharma company outlook to 2016INTRODUCTIONData sourcing[Missing title]Further readingSTRATEGIC INSIGHTTwo companies drive Mid Pharma growthGilead and Celgene growth driversThree companies face declinesTHE MID PHARMA OUTLOOK TO 2016Overview of Mid Pharma to 2016Mid Pharma prescription pharma sales performance, 2004–16Mid Pharma landscape, 2010–16Mid Pharma company analysisMid Pharma launch/core/expiry analysisMid Pharma therapy area analysisMid Pharma molecule type analysisAPPENDIXReferencesExchange rates

To order this report:Pharmaceutical Industry: Mid Pharma Company Outlook to 2016

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker